Clinical Trials
45 trialsNCT06607458 2026-06-01
DEL-LIVER
Delcath Systems Inc.
Phase 2 Recruiting
NCT05723562 2026-05-26
AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT05513742 2026-05-06
COMPANION-003
Compass Therapeutics
Phase 2 Completed
NCT05009069 2026-04-21
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting
NCT06640049 2025-11-17
China AZUR-1
GlaxoSmithKline
Phase 2 Active not recruiting
NCT02399813 2023-03-20
A Phase 2 Study of Axalimogene Filolisbac (ADXS11-001) in Participants With Carcinoma of the Anorectal Canal
Advaxis, Inc.
Phase 2 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT01915472 2021-08-19
A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer
Gilead Sciences
Phase 2 Withdrawn
NCT00361842 2021-07-02
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT01609231 2020-05-04
MK-0646-025
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT02425683 2020-02-10
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
US Oncology Research
Phase 2 Terminated
NCT01111604 2019-08-06
A Study of Ramucirumab or Icrucumab in Colorectal Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02305758 2018-11-20
Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00094809 2018-10-17
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Amgen
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00845039 2018-07-02
FC-4
Eli Lilly and Company
Phase 2 Terminated
NCT00865189 2017-08-04
INOVA
Hoffmann-La Roche
Phase 2 Completed
NCT01507103 2017-01-13
SPRINT
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT02694718 2017-01-11
A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00527111 2016-11-03
Pre-op Rectal ChemoRad +/- Cetuximab
US Oncology Research
Phase 2 Completed
NCT00813605 2016-10-27
QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma
NantCell, Inc.
Phase 2 Completed
NCT00454116 2016-10-07
A Phase II, Double Blind Study of 2 Doses of ZACTIMAâ„¢(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients
Sanofi
Phase 2 Completed
NCT00851084 2016-06-07
AFFIRM
Sanofi
Phase 2 Completed
NCT00022698 2016-04-15
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT00752570 2015-09-02
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Amgen
Phase 2 Completed
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT01075399 2013-08-30
HX4-200
Siemens Molecular Imaging
Phase 2 Completed
NCT00707889 2013-05-15
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
AbbVie
Phase 2 Completed
NCT00111774 2013-05-14
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Amgen
Phase 2 Completed
NCT00988936 2012-08-22
K5-101
Siemens Molecular Imaging
Phase 2 Completed
NCT00080834 2012-05-16
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
Daiichi Sankyo
Phase 2 Completed
NCT00137878 2012-02-23
TNFeradeâ„¢ Plus Chemo/Radiation/Surgery for Rectal Cancer
GenVec
Phase 2 Completed
NCT00113776 2011-01-21
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
Amgen
Phase 2 Completed
NCT00421824 2011-01-04
Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer
Sanofi
Phase 2 Completed
NCT00174616 2009-12-07
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Sanofi
Phase 2 Completed
NCT00263029 2009-09-18
PROCTFUL
Sanofi
Phase 2 Completed
NCT00063427 2009-08-21
Study Evaluating MAC-321 in Colorectal Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00072748 2009-08-21
Study Evaluating EKB-569 in Advanced Colorectal Cancer
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00330915 2009-07-21
A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.
Eli Lilly and Company
Phase 2 Completed
NCT00235898 2008-08-25
Clinical Trial in Patients With Metastatic Colorectal Cancer
Mast Therapeutics, Inc.
Phase 2 Completed
NCT00590278 2008-01-25
TOMUDEX
AstraZeneca
Phase 2 Completed
NCT00081627 2007-11-27
Clinical Trial in Patients With Metastatic Colorectal Cancer
Mast Therapeutics, Inc.
Phase 2 Completed